An Act providing for certification of buprenorphine office-based prescribers; limiting the use of buprenorphine; and imposing powers and duties on the Department of Drug and Alcohol Programs.
Bill status
passed
3 of 5 stages cleared
Introduction
May 2019
Committee Review
Jun 2019
Senate Passage
Jun 2019
House Passage
Governor
Introduced May 28, 2019
Last action Jun 18, 2019
Floor votes · Senate Jun 17, 2019
How they voted
26–7
Passed
Total votes 33
Jun 17, 2019
D
Democratic14
64% Yea
R
Republican19
89% Yea
Vote distribution
All Yea
All Nay
Mixed
No data
Full legislative history
Actions timeline
Total actions
8
Key actions
3
Committee
5
Jun 18, 2019
Committee
Referred to HUMAN SERVICES
lower
Jun 17, 2019
Upper · Passed
Third consideration and final passage
upper
Jun 10, 2019
Upper · Passed
Re-reported as committed
upper
Jun 5, 2019
Committee
Re-referred to APPROPRIATIONS
upper
Jun 4, 2019
Upper · Passed
Reported as committed
upper
May 28, 2019
Committee
PN 0820 Referred to HEALTH AND HUMAN SERVICES
upper
0 primary · 5 co-sponsors
Sponsors
No sponsor information available.
Ask Maddy
·
AI policy assistant
Ask Maddy about SB 675
Scope: PA
Hi! I can help you understand SB 675. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline